696 related articles for article (PubMed ID: 24703899)
1. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
2. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
3. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
4. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
5. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
Dreicer R
Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
[TBL] [Abstract][Full Text] [Related]
6. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
Saad F; Miller K
Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
[TBL] [Abstract][Full Text] [Related]
7. Sequencing Treatment for Castration-Resistant Prostate Cancer.
Handy CE; Antonarakis ES
Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
[TBL] [Abstract][Full Text] [Related]
8. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
[TBL] [Abstract][Full Text] [Related]
9. Castration-resistant prostate cancer: AUA Guideline.
Cookson MS; Roth BJ; Dahm P; Engstrom C; Freedland SJ; Hussain M; Lin DW; Lowrance WT; Murad MH; Oh WK; Penson DF; Kibel AS
J Urol; 2013 Aug; 190(2):429-38. PubMed ID: 23665272
[TBL] [Abstract][Full Text] [Related]
10. Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer.
Maroto P; Solsona E; Gallardo E; Mellado B; Morote J; Arranz JÁ; Gómez-Veiga F; Unda M; Climent MÁ; Alcaraz A
Crit Rev Oncol Hematol; 2016 Apr; 100():127-36. PubMed ID: 26363809
[TBL] [Abstract][Full Text] [Related]
11. Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Cereda V; Formica V; Massimiani G; Tosetto L; Roselli M
Expert Opin Investig Drugs; 2014 Apr; 23(4):469-87. PubMed ID: 24490883
[TBL] [Abstract][Full Text] [Related]
12. Current therapeutic options in metastatic castration-resistant prostate cancer.
Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis C; Mahal B; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro CJ; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur J Cancer; 2023 May; 185():178-215. PubMed ID: 37003085
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Bracarda S; Logothetis C; Sternberg CN; Oudard S
BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
MacVicar GR; Hussain MH
Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
[TBL] [Abstract][Full Text] [Related]
16. Management of patients with castration-resistant disease.
Pezaro C; Omlin A; Lorente D; de Bono J
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1243-60, ix. PubMed ID: 24188261
[TBL] [Abstract][Full Text] [Related]
17. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
19. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.
Nussbaum N; George DJ; Abernethy AP; Dolan CM; Oestreicher N; Flanders S; Dorff TB
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):111-21. PubMed ID: 26832363
[TBL] [Abstract][Full Text] [Related]
20. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]